Skip to main content
Erschienen in: Drugs & Aging 5/2005

01.05.2005 | Review Article

The Impact of Age on Rejection in Kidney Transplantation

verfasst von: Dr Johan W. de Fijter

Erschienen in: Drugs & Aging | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

The time to failure of a renal allograft is determined by the initial function achieved after transplantation, the number and severity of insults to the graft, and a number of tissue characteristics. The insults a graft usually encounters include ischaemia/reperfusion injury, acute rejection episodes, drug-related nephrotoxicity, hypertension and hyperlipidaemia. Important tissue characteristics include susceptibility to injury and the ability of the tissue to repair damage.
Elderly transplant recipients are considered poor immune responders but if a single acute rejection episode occurs this is more likely to significantly shorten graft and patient survival in this age group. Two issues have been identified with the use of old (>50 years of age) donor kidneys. First, compared with kidneys from younger donors, they have an increased incidence of acute interstitial rejection. Secondly, once a rejection episode occurs, the ability to mount a tissue repair process seems impaired. An explanation for the increased loss of grafts from old donors that have experienced acute rejection episodes is that such kidneys have fewer nephrons that function adequately and that the cumulated effect of damage results in an earlier demise of the graft compared with younger donor kidneys. Alternatively, graft parenchymal cells may undergo premature senescence or aging as a result of multiple injuries and repair. If progressive loss of renal mass or senescence is the mechanism responsible for increased graft loss, then it is expected that grafts from older donors will show a progressive decrease in function over time and that the rate of decline of function will correlate with donor age. We have suggested that increased graft loss of older donor kidneys results from increased incidence of acute rejection episodes in the early post-transplantation months together with a partly impaired ability to repair the tissue.
Drug pharmacokinetic parameters are generally little influenced by age. However, the degree to which drugs suppress the immune system, and the extent to which kidneys from older donors are susceptible to the nephrotoxic effects of certain drugs, are unpredictable. There appears to be a more delicate balance between adequate immunosuppression and excess nonimmune toxicity in patients receiving older kidneys. Outcome parameters in elderly renal transplant recipients are currently dominated by increased death from infectious disease and drug-related (cardiovascular) causes. Increased susceptibility to nephrotoxic drugs, and to calcineurin inhibitors in particular, may be related to the increased risk of allograft failure experienced by the elderly as a surrogate for chronic allograft nephropathy.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–30PubMedCrossRef Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–30PubMedCrossRef
2.
Zurück zum Zitat Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13: 1358–64PubMedCrossRef Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13: 1358–64PubMedCrossRef
3.
Zurück zum Zitat Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605–12PubMedCrossRef Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605–12PubMedCrossRef
4.
Zurück zum Zitat Gjertson DW. A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS update. Clin Transpl 1996: 343–60 Gjertson DW. A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS update. Clin Transpl 1996: 343–60
6.
Zurück zum Zitat Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167–81PubMed Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167–81PubMed
7.
Zurück zum Zitat Sijpkens YW, Doxiadis II, de Fijter JW, et al. Sharing crossreactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56: 1920–7PubMedCrossRef Sijpkens YW, Doxiadis II, de Fijter JW, et al. Sharing crossreactive groups of MHC class I improves long-term graft survival. Kidney Int 1999; 56: 1920–7PubMedCrossRef
8.
Zurück zum Zitat Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. J Am Soc Nephrol 2002; 13: 1067–72PubMed Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. J Am Soc Nephrol 2002; 13: 1067–72PubMed
9.
Zurück zum Zitat Roodnat JI, Zietse R, Mulder PG, et al. The vanishing importance of age in renal transplantation. Transplantation 1999; 67: 576–80PubMedCrossRef Roodnat JI, Zietse R, Mulder PG, et al. The vanishing importance of age in renal transplantation. Transplantation 1999; 67: 576–80PubMedCrossRef
10.
Zurück zum Zitat Takemoto S, Terasaki PI. Donor age and recipient age. Clin Transpl 1988; 3: 345–56 Takemoto S, Terasaki PI. Donor age and recipient age. Clin Transpl 1988; 3: 345–56
11.
Zurück zum Zitat Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885–9PubMedCrossRef Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885–9PubMedCrossRef
12.
Zurück zum Zitat Meier-Kriesche HU, Ojo AO, Cibrik DM, et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70: 306–10PubMedCrossRef Meier-Kriesche HU, Ojo AO, Cibrik DM, et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70: 306–10PubMedCrossRef
13.
Zurück zum Zitat de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538–46PubMed de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538–46PubMed
14.
Zurück zum Zitat Cecka JM. The UNOS Scientific Renal Transplant Registry: ten years of kidney transplants. Clin Transpl 1997; 13: 1–14 Cecka JM. The UNOS Scientific Renal Transplant Registry: ten years of kidney transplants. Clin Transpl 1997; 13: 1–14
15.
Zurück zum Zitat Cohen B, Persijn GG, de Meester J. Annual report. Leiden: Eurotransplant International Foundation, 1999 Cohen B, Persijn GG, de Meester J. Annual report. Leiden: Eurotransplant International Foundation, 1999
16.
Zurück zum Zitat Terasaki PI, Gjertson DW, Cecka JM, et al. Significance of the donor age effect on kidney transplants. Clin Transpl 1997; 11: 366–72 Terasaki PI, Gjertson DW, Cecka JM, et al. Significance of the donor age effect on kidney transplants. Clin Transpl 1997; 11: 366–72
17.
Zurück zum Zitat Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333–6PubMedCrossRef Terasaki PI, Cecka JM, Gjertson DW, et al. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333–6PubMedCrossRef
18.
Zurück zum Zitat Cecka JM. Living donor transplants. Clin Transpl 1995; 11: 363–77 Cecka JM. Living donor transplants. Clin Transpl 1995; 11: 363–77
19.
Zurück zum Zitat Terasaki PI, Cecka JM, Gjertson DW, et al. Spousal and other living renal donor transplants. Clin Transpl 1997; 13: 269–84 Terasaki PI, Cecka JM, Gjertson DW, et al. Spousal and other living renal donor transplants. Clin Transpl 1997; 13: 269–84
20.
Zurück zum Zitat Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–85PubMed Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278–85PubMed
21.
Zurück zum Zitat Dodane V, Chevalier J, Bariety J, et al. Longitudinal study of solute excretion and glomerular ultrastructure in an experimental model of aging rats free of kidney disease. Lab Invest 1991; 64: 377–91PubMed Dodane V, Chevalier J, Bariety J, et al. Longitudinal study of solute excretion and glomerular ultrastructure in an experimental model of aging rats free of kidney disease. Lab Invest 1991; 64: 377–91PubMed
22.
Zurück zum Zitat Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 1106–22PubMed Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7: 1106–22PubMed
23.
Zurück zum Zitat Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992; 232: 194–201PubMedCrossRef Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney weight, and body surface in normal man. Anat Rec 1992; 232: 194–201PubMedCrossRef
24.
Zurück zum Zitat Curschellas E, Landmann J, Durig M, et al. Morphologic findings in ‘zero-hour’ biopsies of renal transplants. Clin Nephrol 1991; 36: 215–22PubMed Curschellas E, Landmann J, Durig M, et al. Morphologic findings in ‘zero-hour’ biopsies of renal transplants. Clin Nephrol 1991; 36: 215–22PubMed
25.
Zurück zum Zitat Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex: a quantitative study. Virchows Arch A Pathol Anat Histol 1980; 387: 271–7PubMedCrossRef Kappel B, Olsen S. Cortical interstitial tissue and sclerosed glomeruli in the normal human kidney, related to age and sex: a quantitative study. Virchows Arch A Pathol Anat Histol 1980; 387: 271–7PubMedCrossRef
26.
Zurück zum Zitat Seron D, Carrera M, Grino JM, et al. Relationship between donor renal interstitial surface and post-transplant function. Nephrol Dial Transplant 1993; 8: 539–43PubMed Seron D, Carrera M, Grino JM, et al. Relationship between donor renal interstitial surface and post-transplant function. Nephrol Dial Transplant 1993; 8: 539–43PubMed
27.
Zurück zum Zitat Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol 1998; 9: 699–709PubMed Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol 1998; 9: 699–709PubMed
28.
Zurück zum Zitat Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37: 601–11PubMedCrossRef Kang DH, Anderson S, Kim YG, et al. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37: 601–11PubMedCrossRef
29.
Zurück zum Zitat Cecka JM, Terasaki PI. Optimal use for older donor kidneys: older recipients. Transplant Proc 1995; 27: 801–2PubMed Cecka JM, Terasaki PI. Optimal use for older donor kidneys: older recipients. Transplant Proc 1995; 27: 801–2PubMed
30.
Zurück zum Zitat Gjertson DW, Terasaki PI, Cecka JM, et al. Senior citizens pool for aged kidneys [abstract]. Transplant Proc 1997; 29: 129PubMedCrossRef Gjertson DW, Terasaki PI, Cecka JM, et al. Senior citizens pool for aged kidneys [abstract]. Transplant Proc 1997; 29: 129PubMedCrossRef
31.
Zurück zum Zitat Fagiolo U, Amadori A, Biselli R, et al. Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly: humoral immune response enhancement by thymostimulin. Vaccine 1993; 11: 1336–40PubMedCrossRef Fagiolo U, Amadori A, Biselli R, et al. Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly: humoral immune response enhancement by thymostimulin. Vaccine 1993; 11: 1336–40PubMedCrossRef
32.
Zurück zum Zitat Gillis S, Kozak R, Durante M, et al. Immunological studies of aging: decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest 1981; 67: 937–42PubMedCrossRef Gillis S, Kozak R, Durante M, et al. Immunological studies of aging: decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest 1981; 67: 937–42PubMedCrossRef
33.
Zurück zum Zitat Whisler RL, Liu B, Wu LC, et al. Reduced activation of transcriptional factor AP-1 among peripheral blood T cells from elderly humans after PHA stimulation: restorative effect of phorbol diesters. Cell Immunol 1993; 152: 96–109PubMedCrossRef Whisler RL, Liu B, Wu LC, et al. Reduced activation of transcriptional factor AP-1 among peripheral blood T cells from elderly humans after PHA stimulation: restorative effect of phorbol diesters. Cell Immunol 1993; 152: 96–109PubMedCrossRef
34.
Zurück zum Zitat Palomar R, Ruiz JC, Zubimendi JA, et al. Acute rejection in the elderly recipient: influence of age in the outcome of kidney transplantation. Int Urol Nephrol 2002; 33: 145–8PubMedCrossRef Palomar R, Ruiz JC, Zubimendi JA, et al. Acute rejection in the elderly recipient: influence of age in the outcome of kidney transplantation. Int Urol Nephrol 2002; 33: 145–8PubMedCrossRef
35.
Zurück zum Zitat Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004; 19Suppl. 3: iii11–5PubMedCrossRef Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004; 19Suppl. 3: iii11–5PubMedCrossRef
36.
Zurück zum Zitat Moreso F, Seron D, Gil-Vernet S, et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 1999; 14: 930–5PubMedCrossRef Moreso F, Seron D, Gil-Vernet S, et al. Donor age and delayed graft function as predictors of renal allograft survival in rejection-free patients. Nephrol Dial Transplant 1999; 14: 930–5PubMedCrossRef
37.
Zurück zum Zitat Boom H, Mallat MJ, de Fijter JW, et al. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859–66PubMedCrossRef Boom H, Mallat MJ, de Fijter JW, et al. Delayed graft function influences renal function, but not survival. Kidney Int 2000; 58: 859–66PubMedCrossRef
38.
Zurück zum Zitat Cho YW. Expanded criteria donors. Clin Transpl 1998; 14: 421–36 Cho YW. Expanded criteria donors. Clin Transpl 1998; 14: 421–36
39.
Zurück zum Zitat Knight RJ, Burrows L, Bodian C. The influence of acute rejection on long-term renal allograft survival: a comparison of living and cadaveric donor transplantation. Transplantation 2001; 72: 69–76PubMedCrossRef Knight RJ, Burrows L, Bodian C. The influence of acute rejection on long-term renal allograft survival: a comparison of living and cadaveric donor transplantation. Transplantation 2001; 72: 69–76PubMedCrossRef
40.
Zurück zum Zitat Basar H, Soran A, Shapiro R, et al. Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999; 67: 1191–3PubMedCrossRef Basar H, Soran A, Shapiro R, et al. Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999; 67: 1191–3PubMedCrossRef
41.
Zurück zum Zitat Waiser J, Schreiber M, Budde K, et al. Age-matching in renal transplantation. Nephrol Dial Transplant 2000; 15: 696–700PubMedCrossRef Waiser J, Schreiber M, Budde K, et al. Age-matching in renal transplantation. Nephrol Dial Transplant 2000; 15: 696–700PubMedCrossRef
42.
Zurück zum Zitat The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–37CrossRef The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029–37CrossRef
43.
Zurück zum Zitat Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321–5 Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321–5
44.
Zurück zum Zitat Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225–32PubMedCrossRef Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225–32PubMedCrossRef
45.
Zurück zum Zitat Sanchez-Fructuoso AI, Prats D, Marques M, et al. Does renal mass exert an independent effect on the determinants of antigen-dependent injury? Transplantation 2001; 71: 381–6PubMedCrossRef Sanchez-Fructuoso AI, Prats D, Marques M, et al. Does renal mass exert an independent effect on the determinants of antigen-dependent injury? Transplantation 2001; 71: 381–6PubMedCrossRef
46.
Zurück zum Zitat Prommool S, Jhangri GS, Cockfield SM, et al. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11: 565–73PubMed Prommool S, Jhangri GS, Cockfield SM, et al. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11: 565–73PubMed
47.
Zurück zum Zitat Ferguson RM. Aspects of allograft rejection: II. Risk factors in renal allograft rejection. Transplant Rev 1995, 6 Ferguson RM. Aspects of allograft rejection: II. Risk factors in renal allograft rejection. Transplant Rev 1995, 6
48.
Zurück zum Zitat van Saase JL, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995; 59: 1280–5PubMed van Saase JL, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995; 59: 1280–5PubMed
49.
50.
Zurück zum Zitat Halloran PF, Homik J, Goes N, et al. The ‘injury response’: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79–81PubMedCrossRef Halloran PF, Homik J, Goes N, et al. The ‘injury response’: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29: 79–81PubMedCrossRef
51.
Zurück zum Zitat Khoruts A, Mondino A, Pape KA, et al. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 1998; 187: 225–36PubMedCrossRef Khoruts A, Mondino A, Pape KA, et al. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J Exp Med 1998; 187: 225–36PubMedCrossRef
52.
Zurück zum Zitat Shoskes DA, Parfrey NA, Halloran PF. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation 1990; 49: 201–7PubMedCrossRef Shoskes DA, Parfrey NA, Halloran PF. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation 1990; 49: 201–7PubMedCrossRef
53.
Zurück zum Zitat Penfield JG, Wang Y, Li S, et al. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney. Kidney Int 1999; 56: 1759–69PubMedCrossRef Penfield JG, Wang Y, Li S, et al. Transplant surgery injury recruits recipient MHC class II-positive leukocytes into the kidney. Kidney Int 1999; 56: 1759–69PubMedCrossRef
54.
Zurück zum Zitat Lu CY, Penfield JG, Kielar ML, et al. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int 1999; 55: 2157–68PubMedCrossRef Lu CY, Penfield JG, Kielar ML, et al. Hypothesis: is renal allograft rejection initiated by the response to injury sustained during the transplant process? Kidney Int 1999; 55: 2157–68PubMedCrossRef
55.
Zurück zum Zitat Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol 2001; 12: 385–93PubMed Melk A, Halloran PF. Cell senescence and its implications for nephrology. J Am Soc Nephrol 2001; 12: 385–93PubMed
56.
Zurück zum Zitat Kasiske BL. The influence of donor age on renal function in transplant recipients. Am J Kidney Dis 1988; 11: 248–53PubMed Kasiske BL. The influence of donor age on renal function in transplant recipients. Am J Kidney Dis 1988; 11: 248–53PubMed
57.
Zurück zum Zitat Kerr SR, Gillingham KJ, Johnson EM, et al. Living donors >55 years: to use or not to use? Transplantation 1999; 67: 999–1004PubMedCrossRef Kerr SR, Gillingham KJ, Johnson EM, et al. Living donors >55 years: to use or not to use? Transplantation 1999; 67: 999–1004PubMedCrossRef
58.
Zurück zum Zitat Newstead CG, Dyer PA. The influence of increased age and age matching on graft survival after first cadaveric renal transplantation. Transplantation 1992; 54: 441–3PubMedCrossRef Newstead CG, Dyer PA. The influence of increased age and age matching on graft survival after first cadaveric renal transplantation. Transplantation 1992; 54: 441–3PubMedCrossRef
59.
Zurück zum Zitat Smits JM, Persijn GG, van Houwelingen HC, et al. Evaluation of the Eurotransplant Senior Program: the results of the first year. Am J Transplant 2002; 2: 664–70PubMedCrossRef Smits JM, Persijn GG, van Houwelingen HC, et al. Evaluation of the Eurotransplant Senior Program: the results of the first year. Am J Transplant 2002; 2: 664–70PubMedCrossRef
61.
Zurück zum Zitat Dimeny E, Wahlberg J, Larsson E, et al. Can histopathological findings in early renal-allograft biopsies identify patients at risk for chronic vascular rejection. Clin Transplant 1995; 9: 79–84PubMed Dimeny E, Wahlberg J, Larsson E, et al. Can histopathological findings in early renal-allograft biopsies identify patients at risk for chronic vascular rejection. Clin Transplant 1995; 9: 79–84PubMed
62.
Zurück zum Zitat Isoniemi HM, Krogerus L, von Willebrand E, et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155–60PubMedCrossRef Isoniemi HM, Krogerus L, von Willebrand E, et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155–60PubMedCrossRef
63.
Zurück zum Zitat Vercauteren SB, Bosnians JL, Elseviers MM, et al. A metaanalysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 1998; 54: 536–45PubMedCrossRef Vercauteren SB, Bosnians JL, Elseviers MM, et al. A metaanalysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 1998; 54: 536–45PubMedCrossRef
64.
Zurück zum Zitat Lindelow B, Bergh CH, Herlitz H, et al. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11: 951–7PubMed Lindelow B, Bergh CH, Herlitz H, et al. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 2000; 11: 951–7PubMed
65.
Zurück zum Zitat Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931–40PubMedCrossRef Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931–40PubMedCrossRef
66.
Zurück zum Zitat Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients: a seven-year follow-up. Transplantation 1990; 50: 589–93PubMedCrossRef Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients: a seven-year follow-up. Transplantation 1990; 50: 589–93PubMedCrossRef
67.
Zurück zum Zitat Franceschini N, Alpers CE, Bennett WM, et al. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 1998; 32: 247–53PubMedCrossRef Franceschini N, Alpers CE, Bennett WM, et al. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 1998; 32: 247–53PubMedCrossRef
68.
Zurück zum Zitat Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910–7PubMed Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910–7PubMed
69.
Zurück zum Zitat Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610–4PubMedCrossRef Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610–4PubMedCrossRef
70.
Zurück zum Zitat Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 1027–34PubMedCrossRef Bakker RC, Hollander AA, Mallat MJ, et al. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003; 64: 1027–34PubMedCrossRef
71.
Zurück zum Zitat Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999; 15: 197–205PubMedCrossRef Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999; 15: 197–205PubMedCrossRef
72.
Zurück zum Zitat Schnuelle P, Der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536–43PubMed Schnuelle P, Der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536–43PubMed
73.
Zurück zum Zitat Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653–60PubMedCrossRef Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653–60PubMedCrossRef
74.
Zurück zum Zitat Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143–8PubMed Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143–8PubMed
75.
Zurück zum Zitat Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048–53PubMedCrossRef Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048–53PubMedCrossRef
76.
Zurück zum Zitat Opelz G, Dohler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72: 1267–73PubMedCrossRef Opelz G, Dohler B. Cyclosporine and long-term kidney graft survival. Transplantation 2001; 72: 1267–73PubMedCrossRef
77.
Zurück zum Zitat Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995; 17: 621–4PubMedCrossRef Kahan BD, Welsh M, Rutzky LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995; 17: 621–4PubMedCrossRef
78.
Zurück zum Zitat Meier-Kriesche HU, Kaplan B, Brannan P, et al. A limited sampling strategy for the estimation of eight-hour Neoral areas under the curve in renal transplantation. Ther Drug Monit 1998; 20: 401–7PubMedCrossRef Meier-Kriesche HU, Kaplan B, Brannan P, et al. A limited sampling strategy for the estimation of eight-hour Neoral areas under the curve in renal transplantation. Ther Drug Monit 1998; 20: 401–7PubMedCrossRef
79.
Zurück zum Zitat Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129–34PubMed Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 2129–34PubMed
80.
Zurück zum Zitat Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55–62PubMedCrossRef Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55–62PubMedCrossRef
81.
Zurück zum Zitat Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789–95PubMedCrossRef Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789–95PubMedCrossRef
82.
Zurück zum Zitat International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148–56CrossRef International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148–56CrossRef
83.
Zurück zum Zitat Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157–66CrossRef Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157–66CrossRef
84.
Zurück zum Zitat Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024–32CrossRef Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024–32CrossRef
85.
Zurück zum Zitat Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003; 18: 1201–8PubMedCrossRef Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 2003; 18: 1201–8PubMedCrossRef
86.
Zurück zum Zitat Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194–202PubMedCrossRef Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194–202PubMedCrossRef
87.
Zurück zum Zitat MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271–80PubMedCrossRef MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271–80PubMedCrossRef
88.
Zurück zum Zitat Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059–71PubMed Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059–71PubMed
89.
Zurück zum Zitat Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20: 123–33PubMedCrossRef Napoli KL, Wang ME, Stepkowski SM, et al. Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 1998; 20: 123–33PubMedCrossRef
90.
Zurück zum Zitat Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777–86PubMedCrossRef Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777–86PubMedCrossRef
91.
Zurück zum Zitat Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18(1): 22–8PubMedCrossRef Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18(1): 22–8PubMedCrossRef
92.
Zurück zum Zitat Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741–6PubMedCrossRef Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741–6PubMedCrossRef
93.
Zurück zum Zitat Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141–9PubMedCrossRef Trompeter R, Filler G, Webb NJ, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141–9PubMedCrossRef
94.
Zurück zum Zitat Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775–82PubMedCrossRef Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775–82PubMedCrossRef
95.
Zurück zum Zitat Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980–4PubMedCrossRef Kaplan B, Schold JD, Meier-Kriesche HU. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980–4PubMedCrossRef
96.
Zurück zum Zitat Murphy GJ, Waller JR, Sandford RS, et al. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 2003; 90: 680–6PubMedCrossRef Murphy GJ, Waller JR, Sandford RS, et al. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Br J Surg 2003; 90: 680–6PubMedCrossRef
97.
Zurück zum Zitat Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736–40PubMedCrossRef Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736–40PubMedCrossRef
98.
Zurück zum Zitat Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89–94PubMedCrossRef Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89–94PubMedCrossRef
99.
Zurück zum Zitat Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070–6PubMedCrossRef Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070–6PubMedCrossRef
100.
Zurück zum Zitat Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1998; 14: 1–16 Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1998; 14: 1–16
Metadaten
Titel
The Impact of Age on Rejection in Kidney Transplantation
verfasst von
Dr Johan W. de Fijter
Publikationsdatum
01.05.2005
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 5/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200522050-00007

Weitere Artikel der Ausgabe 5/2005

Drugs & Aging 5/2005 Zur Ausgabe

Review Article

Dextropropoxyphene

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.